| Drug 1 | |
| Generic/Working Name | Merestinib |
| Trade Name | NA |
| Company Name | Eli Lilly and Company |
| Drug Type | Multikinase inhibitor |
| Drug Class | Small molecule |
| Dose | 80 mg |
| Route | oral (po) |
| Schedule of Administration | Continuous QD |
| Drug 2 | |
| Generic/Working Name | Ramucirumab |
| Trade Name | Cyramza® |
| Company Name | Eli Lilly and Company |
| Drug Type | VEGFR2 inhibitor |
| Drug Class | Antibody |
| Dose | 8 mg/kg |
| Route | IV |
| Schedule of Administration | Day 1 and day 15 over a 28‐day cycle |
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.